Key result
JA16 myostatin blockade improves muscle size and force more in newborn than older mdx mice.
Why the study?
Myostatin blockade is promising for increasing muscle mass in Duchenne muscular dystrophy, but clinical translation faces challenges partly due to the progressive nature of the disease.
Does JA16 monoclonal antibody-mediated myostatin blockade improve the dystrophic phenotype in newborn mdx mice more effectively than in older mdx mice?
Does JA16 monoclonal antibody-mediated myostatin blockade improve the dystrophic phenotype in newborn mdx mice more effectively than in older mdx mice?
Early myostatin blockade in newborn mdx mice provides greater therapeutic benefits for dystrophic phenotypes compared to later intervention, demonstrating an age-dependent effect.
Greater benefits from early myostatin blockade in mdx models; hypothesis-generating for timing in human DMD trials.
Myostatin (GDF8) is a member of the transforming growth factor-β (TGF-β) superfamily. Myostatin gene mutations or inhibition of the Myostatin/Activin pathway results in increased skeletal muscle mass, demonstrating its role as a negative regulator of skeletal muscle. Myostatin blockade is a promising strategy for increasing muscle mass in myopathies such as Duchenne Muscular Dystrophy (DMD); however, it faces considerable challenges in clinical translation, in part due to the progressive nature of the disease. Here we tested the ability of JA16 monoclonal antibody-mediated myostatin blockade to improve the dystrophic phenotype in newborn mdx mice (an animal model of DMD). Myostatin inhibition led to significant increases in muscle size, fiber number and cross-sectional area along with increased absolute force alongside reduced post-eccentric contraction force drop and reduced serum creatine kinase. We used the Multiparametric Muscle Improvement Score (MMIS) to objectively quantitate benefits in this preclinical study and determined that the magnitude of improvements exceeded those reported using the exact same intervention in older mdx mice treated for the same duration. This study demonstrates an age-dependent aspect of this intervention and suggests that earlier interventions may provide greater therapeutic benefits.
No takes yet. Share an insight, caveat, or question.
Bogdanovich et al. (2026) studied Duchenne Muscular Dystrophy (DMD). JA16 monoclonal antibody-mediated myostatin blockade vs. Older mdx mice (historical comparison) was evaluated on Dystrophic phenotype improvement (muscle size, fiber number, cross-sectional area, absolute force, and Multiparametric Muscle Improvement Score). JA16 monoclonal antibody-mediated myostatin blockade significantly improved muscle size and force in newborn mdx mice, with benefits exceeding those reported in older mice.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: